Form 4: Zimmer Biomet CFO Earns 10,217 Performance RSUs

Zimmer Biomet Holdings, Inc.'s Executive VP and CFO, Suketu Upadhyay, earned 10,217 performance-based Restricted Stock Units, which are set to vest on March 6, 2026.

Summary

• Suketu Upadhyay, Executive VP and CFO of Zimmer Biomet Holdings, Inc. (ZBH), reported the earning of performance-based Restricted Stock Units (RSUs).
• A total of 10,217 RSUs were earned, determined on February 19, 2026, based on performance conditions met during the 2023-2025 period.
• These RSUs represent a contingent right to receive one share of Company common stock each.
• The RSUs will vest on March 6, 2026.
• The original grant date for these performance-based RSUs was March 6, 2023.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting successful achievement of performance targets and reinforcing management's alignment with shareholder interests through equity compensation.

Positives

• The earning of performance-based RSUs indicates that the company's performance conditions for the 2023-2025 period were met, suggesting positive operational results.
• This compensation structure aligns the interests of the Executive VP and CFO with those of shareholders, as the value of the RSUs is tied to the company's stock performance.

Negatives

• No specific negative information is contained within this routine insider transaction filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The 10,217 performance-based Restricted Stock Units earned by Suketu Upadhyay are scheduled to vest on March 6, 2026, at which point they will convert into shares of Zimmer Biomet common stock.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that the grant and vesting of performance-based Restricted Stock Units are a standard component of executive compensation packages in the medical technology and healthcare industry, designed to incentivize long-term performance and align executive interests with shareholder value creation.

Comparison to Industry Standards

• Executive compensation through performance-based equity awards, such as RSUs, is a common practice across the S&P 500 and particularly within the medical device sector, including peers like Stryker Corporation (SYK) and Johnson & Johnson (JNJ), which frequently utilize similar long-term incentive plans to retain and motivate key executives.
• The structure, tying the number of earned units to specific performance conditions over a multi-year period (2023-2025), is consistent with best practices for corporate governance, ensuring compensation is directly linked to company achievements rather than solely time-based vesting.

Stakeholder Impact

• Shareholders: The earning of performance-based RSUs by a key executive suggests the company met its performance targets, which is generally positive for shareholders. It also reinforces alignment between executive incentives and shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The 10,217 performance-based Restricted Stock Units will vest on March 6, 2026.

Key Dates

Keywords

Zimmer Biomet, ZBH, Suketu Upadhyay, Form 4, Restricted Stock Units, RSUs, Executive Compensation, Insider Transaction, Performance-based compensation, CFO